MIXED 5-HT1A/D-2 ACTIVITY OF A NEW MODEL OF ARYLPIPERAZINES - 1-ARYL-4-[3-(1,2-DIHYDRONAPHTHALEN-4-YL)-N-PROPYL] PIPERAZINES .1. SYNTHESIS AND STRUCTURE-ACTIVITY-RELATIONSHIPS

被引:44
作者
PERRONE, R
BERARDI, F
COLABUFO, NA
TORTORELLA, V
FIORENTINI, F
OLGIATI, V
VANOTTI, E
GOVONI, S
机构
[1] PIERREL SPA, DEPT R&D, I-20152 MILAN, ITALY
[2] UNIV MILAN, IST SCI FARMACOL, I-20133 MILAN, ITALY
关键词
D O I
10.1021/jm00027a012
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
A new model of 4-alkyl-1-arylpiperazines containing a terminal dihydronaphthalene fragment on the alkyl chain was synthesized in order to have mixed serotonergic and dopaminergic activity and to pursue the recent alternative approaches to the discovery of novel antipsychotic and anxiolytic agents. Title compounds were evaluated for in vitro activity on dopamine D-2 and serotonin 5-HT1A and 5-HT2 receptors by radioreceptor binding assays. They show high nanomolar affinity for 5-HT1A moderate affinity for D-2, and low affinity for 5-HT2 receptors, and in particular, two compounds, 4-[3-(1,2-dihydro-6-methoxynaphthalen-4-yl)-n-propyl] 1-(2-methoxyphenyl)piperazine (8) and 4-[3-(1,2-dihydro-8-methoxynaphthalen-4-yl)-n-propyl]-1-(2-pyridyl)piperazine (15), show values (nM) of IC50 = 2.0 and 1.4 for 5-HT1A and IC50 = 90.6 and 119.3 for D-2, respectively. Some in vivo behavioral studies show compound 8 to be an antagonist on 5-HT1A receptors. These first findings place the new arylpiperazines on the same level as that of the azaspirone class, e.g.,1-(2-methoxyphenyl)-4-[4-(2-phthalimido)-n-butyl]piperazine (NAN-190) and buspirone.
引用
收藏
页码:99 / 104
页数:6
相关论文
共 34 条
[1]  
ANDERSEN PH, 1991, DRUG NEWS PERSPECT, V4, P150
[2]   BINDING OF TYPICAL AND ATYPICAL ANTIPSYCHOTICS TO 5-HT1C AND 5-HT2 SITES - CLOZAPINE POTENTLY INTERACTS WITH 5-HT1C SITES [J].
CANTON, H ;
VERRIELE, L ;
COLPAERT, FC .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1990, 191 (01) :93-96
[3]   THE EFFICACY OF THE D2 AND 5-HT2 ANTAGONIST RISPERIDONE (R-64-766) IN THE TREATMENT OF CHRONIC PSYCHOSIS - AN OPEN DOSE-FINDING STUDY [J].
CASTELAO, JF ;
FERREIRA, L ;
GELDERS, YG ;
HEYLEN, SLE .
SCHIZOPHRENIA RESEARCH, 1989, 2 (4-5) :411-415
[4]   EFFECT OF SEROTONIN ANTAGONISM IN SCHIZOPHRENIA - A PILOT-STUDY WITH SETOPERONE [J].
CEULEMANS, DLS ;
GELDERS, YG ;
HOPPENBROUWERS, MLJA ;
REYNTJENS, AJM ;
JANSSEN, PAJ .
PSYCHOPHARMACOLOGY, 1985, 85 (03) :329-332
[5]   H-3-SPIROPERIDOL LABELS SEROTONIN RECEPTORS IN RAT CEREBRAL-CORTEX AND HIPPOCAMPUS [J].
CREESE, I ;
SNYDER, SH .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1978, 49 (02) :201-202
[6]   MECHANISMS OF ACTION OF ATYPICAL ANTIPSYCHOTIC-DRUGS - IMPLICATIONS FOR NOVEL THERAPEUTIC STRATEGIES FOR SCHIZOPHRENIA [J].
DEUTCH, AY ;
MOGHADDAM, B ;
INNIS, RB ;
KRYSTAL, JH ;
AGHAJANIAN, GK ;
BUNNEY, BS ;
CHARNEY, DS .
SCHIZOPHRENIA RESEARCH, 1991, 4 (02) :121-156
[7]   NAN-190 - AN ARYLPIPERAZINE ANALOG THAT ANTAGONIZES THE STIMULUS EFFECTS OF THE 5-HT1A AGONIST 8-HYDROXY-2-(DI-N-PROPYLAMINO)TETRALIN (8-OH-DPAT) [J].
GLENNON, RA ;
NAIMAN, NA ;
PIERSON, ME ;
TITELER, M ;
LYON, RA ;
WEISBERG, E .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1988, 154 (03) :339-341
[8]   ARYLPIPERAZINE DERIVATIVES AS HIGH-AFFINITY 5-HT1A SEROTONIN LIGANDS [J].
GLENNON, RA ;
NAIMAN, NA ;
LYON, RA ;
TITELER, M .
JOURNAL OF MEDICINAL CHEMISTRY, 1988, 31 (10) :1968-1971
[9]   CONCEPTS FOR THE DESIGN OF 5-HT(1A) SEROTONIN AGONISTS AND ANTAGONISTS [J].
GLENNON, RA .
DRUG DEVELOPMENT RESEARCH, 1992, 26 (03) :251-274
[10]   SOME ALKYLATION AND GRIGNARD REACTIONS WITH 1-TETRALONES AND RELATED COMPOUNDS [J].
HATTERSLEY, PJ ;
LOCKHART, IM ;
WRIGHT, M .
JOURNAL OF THE CHEMICAL SOCIETY C-ORGANIC, 1969, (02) :217-+